FUTURE OF HEALTHCARE

Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence

Anumana, Inc. | July 14, 2022 | Read time : 2 min

Anumana Collaborates

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.

The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret. The collaboration will initially focus on cardiovascular diseases. Working with its expert partners from Mayo Clinic, Anumana will deploy novel solutions that use AI to analyze an ECG, a widely available, painless test that records the heart’s electrical signals to identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can lead to heart failure. The AI will also screen for atherosclerotic cardiovascular disease, which can lead to heart attack and stroke. In addition, an evidence-based, digital point-of-care solution will be developed to guide in optimizing guideline-directed medical therapies with the aim to lower risk for potentially avoidable hospitalizations and cardiovascular death.

Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms. Bringing together premier global organizations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.”

Murali Aravamudan, CEO of Anumana

“Many heart diseases develop for years before signs and symptoms appear, but the first event may be life threatening,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “AI enables us to uncover hidden signals our bodies transmit to detect otherwise occult heart diseases, potentially years before symptoms appear. This collaboration has the potential to transform the use of a ubiquitous inexpensive test, the ECG, with the aim of democratizing disease detection and helping medical care teams to proactively manage heart disease ahead of time and prevent some clinical events from ever happening.”

“Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care,” said Victor Bulto, President, Novartis Innovative Medicines US. "Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population.”

The Mayo Clinic Cardiology team, led by Dr. Friedman, pioneered the application of AI in cardiology and developed several algorithms based on millions of ECGs, including a low ejection fraction algorithm that received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Further validating the technology, a recent study presented by Mayo Clinic used a modified version of Anumana’s 12-lead ECG algorithm to detect left ventricular dysfunction with single-lead ECGs in smartwatches. These algorithms are licensed to Anumana for development of clinical solutions and have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for marketing authorization through an FDA De Novo request.

About Anumana
Anumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance. 

Spotlight

Healthcare professionals, administrators, and providers agree: it is time to remove the paper from everyday processes like contracting and procurement, HR, Medicare billing, patient onboarding and more. Discover case studies in B2B supply chain management, narcotics ordering and more. Understand the difference between an electronic signature and a digital signature.

Spotlight

Healthcare professionals, administrators, and providers agree: it is time to remove the paper from everyday processes like contracting and procurement, HR, Medicare billing, patient onboarding and more. Discover case studies in B2B supply chain management, narcotics ordering and more. Understand the difference between an electronic signature and a digital signature.

Related News

HEALTH TECHNOLOGY

Smith+Nephew introduces smart glasses into the operating room to enable remote technical support for UK surgeons during procedures

Smith & Nephew | July 11, 2022

Smith+Nephew the global medical technology company, announces a partnership with Rods&Cones to provide smart surgery glasses and digital remote assistance to customers. By providing customers with smart surgery glasses, Smith+Nephew representatives can 'see' through the eyes of the surgeon, instrumentalist nurse, or any healthcare professional using them, enabling continuous remote support before, during, and after surgical interventions. Initially used in the UK to support the NHS and other customers, this solution allows Smith+Nephew to increase its ability to offer technical support for safe and effective use of its products at the right time from anywhere in the world. The increased complexity of surgery, advancement of technologies, and need for productivity and efficiency is enabled by ensuring a specialist is available remotely to give best possible expertise exactly when they need it, in the least disruptive way. "I am delighted that we have agreed to partner with one of the most innovative companies in the area of remote surgical support," said Simon Tarry, Managing Director of Smith+Nephew's UKI/Nordics region. "This new partnership will enable our team to deliver the highest possible expertise exactly when our customers and patients need it. At the same time, I believe enhancing our ability to support our customers remotely serves patient safety and sustainability to great effect." The multi-year agreement with Rods&Cones allows Smith+Nephew to scale its remote support capability for customers, enabling connectivity with specialist surgeons during minimally invasive surgery. The MIS Kit connects seamlessly to a secure Rods&Cones Remote Expert interface, which allows the user to follow and attend a surgery just as if standing in the OR, but with the exact view of the surgeon or other healthcare professional. "We are thrilled to work with such a great company as Smith+Nephew. The achievements they have made in the MedTech industry, especially within the sphere of repair, regeneration and replacement of soft and hard tissue has been awe-inspiring. This partnership between Smith+Nephew and Rods&Cones will be a great step forward and together we will change healthcare for the better." Bruno Dheedene, CEO and Founding Partner of Rods&Cones About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100. The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. About Rods&Cones Rods&Cones' purpose is to be a catalyst of change in healthcare to improve people's lives. The company provides a remote assistance service used to connect medical experts worldwide. With their state-of-the-art technological devices and a digital remote assistance platform, users can connect safely with surgeons, product specialists, or other medical professionals anywhere in the world, in real-time. Rods&Cones was founded in 2017 by two brothers, Bruno and Jan Dheedene. Based in Amsterdam, The Netherlands, the company has now become a leading international supplier of remote surgical assistance services.

Read More

HEALTH TECHNOLOGY

MedSec Sets Up a Healthcare Technology Cyber Risk Management Team

MedSec | July 04, 2022

In order to increase its biological and clinical knowledge, MedSec, a premier solutions provider of medical device security, announced it is forming a new Healthcare Technology Cyber Risk Management (HTCRM) team with a roster of seasoned professionals in the sector. The present Chief Product Officer of MedSec and HTCRM authority Phil Englert will take on the position of Advisor for the new team. "MedSec serves stakeholders of all kinds within the medical device eco-system. The establishment of this team allows us to better serve our hospital clients, who are tackling medical device security on a day-to-day basis." Justine Bone, CEO at MedSec "Biomedical and Clinical Engineering teams already have too many things on their plate – and they need leverage. Becoming an extension of their team, augmented by our technology capabilities, we're able to help our customers do things that they would otherwise not be capable of doing with their existing staff. Our clients love the combination of being able to 'speak tech' but also 'understand clinical' to help them further achieve their goals." Andrew Donarumo, Chief Technology Officer at MedSec Englert will continue to assist MedSec in creating security options for hospitals as an advisor. Englert brings to the position extensive understanding of clinical settings and medical technologies. His experience covers more than 30 years of technical and operational leadership in the healthcare and life sciences sector with an emphasis on creating strategic direction, enhancing operations, and undertaking business optimization and transformation efforts that are enabled by data and technology. In addition to governance and operations, vulnerability and patch management, incident response, medical device alerts, and SOC integration, Phil has led the development of medical device security programmes that have made it possible to prioritise strategic initiatives that will have an impact and carry out efficient maintenance and response tasks. In the past, he oversaw the development of strategy and tactics for a $250 million MedTech services business that supported over 130 Acute Care hospitals in 22 states.

Read More

HEALTH TECHNOLOGY

Trukera™ Medical Launches New ScoutPro™ Osmolarity System

Trukera Medical | September 13, 2022

Trukera™ Medical last week announced a corporate rebranding to reflect thea company’s expanded vision and strategic growth plans targeting broader unmet needs in corneal health. Trukera Medical unveiled the first product under the new company name, the ScoutPro™ Osmolarity System. Designed to help advance corneal health decisions for today’s busy eye care practices, ScoutPro is the first and only portable osmometer in the U.S. “The ScoutPro Osmolarity System is an exciting technology developed around the evolving needs of today’s eye care professionals. Premium cataract and refractive practices are now the fastest growing adopters of osmolarity testing, given the prevalence of hyperosmolarity in their patient demographics and the risk it poses to compromising corneal cell health and driving refractive instability. More than ever, these practices require patient care solutions that can seamlessly adapt into established operational models, not the other way around, to deliver a premium patient experience, efficiency of care, and minimize staff time and disruptions. We’re proud to bring a solution to market addressing these needs, and to help more practices objectively identify and manage such a critical component to patient’s corneal health and refractive outcomes.” Adam Szaronos, Trukera Medical CEO The ScoutPro Osmolarity System brings together nanoliter volume sample collection and analysis in a single portable device. Users can now bring laboratory testing to patients anywhere in the practice to quickly test and provide objective results in the palm of their hand. The system is built upon the company’s established accuracy trusted in over 24 million tests globally to date, with an industry-leading precision. “Toxic hyperosmolarity damages sensitive corneal nerves and may cause refractive instability. As cornea and cataract/refractive specialists, we are cognizant of the importance of this to our surgical outcomes and the overall health of our patients’ eyes. ScoutPro gives us the ability to precisely determine osmolarity quickly and easily, without disrupting patient flow,” said Dr. Lisa Nijm, Chief Medical Advisor for Ophthalmology at Trukera Medical and Corneal Surgeon at Warrenville Eye Care and LASIK Center in Illinois. The ScoutPro Osmolarity System is now available for pre-order in the U.S. and will be commercially launched at the upcoming World Cornea Congress and the American Academy of Ophthalmology later this month. About Trukera Medical Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera Medical’s expanding portfolio includes ScoutPro, the first and only portable osmolarity system in the U.S. The company’s dedicated focus is improving corneal health, both as a primary goal and in preparation for surgery.

Read More